| RESERVED AREA | LANGUAGE

Lung Cancer Study Group

PAP opening to nivolumab + ipilimumab

After the recent opening of two Early Access Programs (PAP) to tepotinib and amivantamab (see news here!) for the treatment of two subtypes of lung cancer, INFARMED granted the request for a PAP to nivolumab in combination with ipilimumab for…

Read More
©2022 Copyright GECP